Stem Cell-Derived Platelet Product Clears China Clinical Entry
Suzhou Xueji Bio reported implied NMPA clinical trial permission for a stem cell-derived allogeneic platelet injection intended for thrombocytopenia associated with cancer treatment and hematologic malignancy, excluding acute promyelocytic leukemia. The program could reduce…
